-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REC-4881 in Solid Tumor
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. REC-4881 in Solid Tumor Drug Details: REC-4881 is under development for the treatment of familial...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REC-4881 in Familial Adenomatous Polyposis
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. REC-4881 in Familial Adenomatous Polyposis Drug Details: REC-4881 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REC-2282 in Neurofibromatoses Type II
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data.REC-2282 in Neurofibromatoses Type IIDrug Details:REC-2282 is under development for the treatment of relapsed or refractory...
-
Product Insights
![]()
Gomo (REC-T-183/197) Field, Brazil
Gomo (REC-T-183/197) upstream field is located in Bahia, Brazil. The upstream field is owned by Alvopetro SA Extracao de Petroleo e Gas Natural. It is operated by Alvopetro SA Extracao de Petroleo e Gas Natural. The project started its operations in 2022. Gomo (REC-T-183/197) Upstream Field profile includes core details such as name, resource type, asset status, stage, owner and equity stakes, operator, product specs (gravity, CO2, sulphur), location, as well as key operational data including production, start and end...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REC-163964 in Clostridioides difficile Infections (Clostridium difficile Associated Disease)
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. REC-163964 in Clostridioides difficile Infections (Clostridium difficile Associated Disease) Drug Details: REC-163964 is under...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – REC-994 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. REC-994 in Cavernous Hemangioma (Cerebral Cavernous Malformation/Cerebral Cavernous Hemangioma) Drug Details: Tempol (REC-994) is under...
-
Thematic Analysis
New![]()
Power Industry Mergers and Acquisitions Deals by Top Themes in Q3 2023 – Thematic Intelligence
This report analyzes the disruptive themes that have driven M&A activity in Q3 2023 in the Power Sector
-
Thematic Analysis
New![]()
Merger and Acquisition Deals of Top Themes by Industries in Q3 2023 – Thematic Intelligence
If you want to understand the themes that drive an industry, simply look at the list of recent mergers and acquisitions (M&As). This report analyzes the disruptive themes that have driven M&A activity in Q3 2023 across all sectors including automotive, basic material, business and consumer services, consumer, energy, financial, healthcare, industrials, real estate, technology, media & telecoms, transportation, infrastructure, and logistics.
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Propranolol Hydrochloride in Retinopathy Of Prematurity
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Propranolol Hydrochloride in Retinopathy Of Prematurity Drug Details:Propranolol hydrochloride (REC-0551) is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Dutogliptin Tartrate in Post-Myocardial Infarction
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Dutogliptin Tartrate in Post-Myocardial Infarction Drug Details: Dutogliptin tartrate (REC-01) is under development for...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ADG-126 in Hepatocellular Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ADG-126 in Hepatocellular Carcinoma Drug Details: ADG-126 is under development for the treatment of advanced...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – ADG-126 in Non-Small Cell Lung Carcinoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. ADG-126 in Non-Small Cell Lung Carcinoma Drug Details: ADG-126 is under development for the treatment...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Lemzoparlimab in Marginal Zone B-cell Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Lemzoparlimab in Marginal Zone B-cell Lymphoma Drug Details: TJC-4 (lemzoparlimab) is under development for the...
-
Product Insights
![]()
China REC/ TITIJYA – The Shore Kota Kinabalu – Sabah
Equip yourself with the essential tools needed to make informed and profitable decisions with our China REC/ TITIJYA - The Shore Kota Kinabalu - Sabah report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
![]()
Lambeth City – Growing Brixton’s Rec Quarter – Greater London
Equip yourself with the essential tools needed to make informed and profitable decisions with our Lambeth City - Growing BrixtonÂ’s Rec Quarter - Greater London report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story: Dive deep...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Ravulizumab LA in Thrombotic Microangiopathy
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Ravulizumab LA in Thrombotic Microangiopathy Drug Details: Ravulizumab (Ultomiris) is a humanized monoclonal antibody. It...
-
Product Insights
![]()
SUEZ Recylg and Rec UK – Darwen Anaerobic Digestion Plant – Lancashire
Equip yourself with the essential tools needed to make informed and profitable decisions with our SUEZ Recylg and Rec UK - Darwen Anaerobic Digestion Plant - Lancashire report./b> Note: This is an on-demand report that will be delivered upon request. The report will be delivered within 2 business days of the purchase, excluding weekends and holidays. Certain sections of the report may be removed or altered based on data availability and relevance. Why choose our report? Unleash the full story:...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – BDB-018 in Solid Tumor
Overview How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. BDB-018 in Solid Tumor Drug Details: BDB-018 is under development for the treatment of...
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Apomorphine in Parkinson’s Disease
OverviewHow likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalDatas proprietary machine learning algorithms developed using over 10 years of historical data.Apomorphine in Parkinson's Disease Drug Details:Staccato apomorphine is under development for the treatment of Parkinson's disease....
-
Product Insights
New![]()
Likelihood of Approval and Phase Transition Success Rate Model – Relatlimab in Non-Hodgkin Lymphoma
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. Relatlimab in Non-Hodgkin Lymphoma Drug Details: Relatlimab (BMS-986016) is under development for the treatment of...
Sign up to receive regular alerts for our latest analysis and reports. No matter your industry focus, you can keep your finger on the pulse with our timely updates.